GlassScriptPhysician profile
Crystal Papak
NPI 1093109886
$6,929.22
in general payments reported to CMS, 2019-2025
22 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $842 · 2022: $417 · 2023: $1,648 · 2024: $2,095 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,655.80 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,744.16 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,143.41 | 2023-2025 | |
| Abbott Laboratories | $671.63 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $662.94 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $598.42 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Glaxosmithkline, LLC. | $553.44 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $311.36 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Amgen INC. | $238.89 | 2021-2025 | Evenity, Prolia, Repatha |
| Idorsia Pharmaceuticals US INC | $208.21 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.78 | 2021-2024 | Jardiance |
| Neurocrine Biosciences, INC. | $137.45 | 2024 | Ingrezza |
| Exact Sciences Corporation | $135.92 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $119.12 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $51.91 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $50.79 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.33 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.41 | 2024 | Trintellix |
| Lundbeck LLC | $22.69 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $21.44 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.72 | 2021 | |
| Currax Pharmaceuticals LLC | $15.98 | 2023 | Contrave |
| Merck Sharp & Dohme LLC | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Papak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.